GLP-1 therapy, often used to aid in weight loss and blood sugar management, works by mimicking the effects of glucagon-like peptide-1 (GLP-1)
After a single intravenous (IV) administration, single intramuscular (IM) administrations at three doses in successive increments along with repeated IM administrations, the elimination half-life (t 1/2 ) of prototype BPC157 was less than 30 min, and BPC157 showed linear pharmacokinetic characteristics in rats and beagle dogs at all doses
K.KolberM
Adipocyte lipolysis assays examining glucagon-receptor-mediated energy expenditure, where retatrutide's GCGR activity differentiates it from GLP-1-only and GLP-1/GIP dual agonists
However, its important to consult with a healthcare provider to fully understand the potential risks and benefits, especially if other underlying conditions, such as diabetes or autoimmune disorders, are present
GH secretagogues alongside TRT